Summary
Vaccination has proved to be an effective means for the prevention of infectious diseases. Advances in our understanding of the human immunodeficiency virus (HIV) and the immune system of the host may lay the foundation for the development of an AIDS vaccine. Current attempts to develop vaccines focus on the development of substances that will produce a different type of immune response from that which occurs naturally. Progress has been made in understanding the mechanisms by which the AIDS virus stimulates an neutralizing antibody response and triggers specific cytotoxic T lymphocytes in the host. The pressing need for a vaccine has prompted the testing of several candidate vaccines based on the simian immunodeficiency virus (closely related to HIV) in the macaque animal model for AIDS. The lessons learned from these trials will be valuable for developing future vaccines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baier M, Werner A, Cichutek K, Garber C, Müller C, Kraus G, Ferdinand FJ, Hartung S, Papas TS, Kurth R, Molecularly cloned simian immunodeficiency virus SIVagm3 is highly divergent from other SIVagm isolates and is biologically active in vitro and in vivo. J Virol 63:5119, 1989
Berman PW, Groopman JE, Gregory T, Weiss RA, Clapham PR, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA, Eichberg JW. HIV-1 challenge of chimpanzees immunized with recombinant gp 120. Proc Natl Acad Sci USA 85:5200, 1988
Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hersershberh RD, Cobb EK, Eichberg J. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345:622, 1990
Binninger D, Ennen J, Bonn D, Norley SG, Kurth R, Mutational analysis of the simian immunodeficiency virus SIVmacnef gene. J Virol 65:5237, 1991
Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dichover R, Donovan R, Luciw PA, Jennings MB, Gardner M, Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses 6:1239, 1990
Cranage MP, Baskerville A, Ashworth LAE, Dennis M, Cook N, Sharpe S, Farrar G, Rose J, Kitchin PA, Greenaway PJ, Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 339:273, 1992
Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, Daniel MD, Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA 86:6353, 1989
Devash Y, Matthews TJ, Drummond JE, Javaherian K, Waters DJ, Arthur LO, Blattner WA, Rusche JR, C-terminal fragments of gp120 and synthetic peptide from five HTLV-III strains: prevalence of antibodies to the HTLV-III MN isolate in infected individuals. AIDS Res Hum Retroviruses 6:307, 1990
Emini EA, Nara PL, Schleif WA, Lewis JA, Davide JP, Lee DR, Kessler J, Conley S, Matsushita S, Putney SD, Gerety RJ, Eichberg JW, Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 64:3674, 1990
Girard M, Kieny MP, Pinter A, Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 88:542, 1991
Hartung S, Norley S, Ennen J, Cichutek K, Plesker R, Kurth R, Vaccine protection against SIVmac infection by high but not low dose whole inactivated virus immunogen. J Acquir Immune Defic Syndr (in press)
Kraus G, Werner A, Baier M, Binninger D, Ferdinand FJ, Norley S, Kurth R, Isolation of human imunodeficiency virus-related simian immunodeficiency viruses from African green monkeys. Proc Natl Acad Sci USA 86:2892, 1989
La Rosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley H, Karplus M, Bolognesi DP, Mathews TJ, Emini EA, Putney SD, Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932, 1990
Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, Ohkawa S, Baskin GB, Zhang JY, Putney SD, Allison AC, Eppstein DA, A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246:1293, 1989
Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J, Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 64:3779, 1990
Nixon DF, Townsend ARM, Elvi JG, Rizza CR, Gallwey J, McMichael AJ, HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336:484, 1988
Norley SG, Kraus G, Ennen J, Bonilla J, König H, Kurth R, Immunological studies of the basis for the apathogenicity of simian immunodeficiency virus from African green monkeys. Proc Natl Acad Sci USA 87:9067, 1990
Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edward JP, Ogunlesi AO, Elwin JG, Rothbard JA, Bangham CRM, Rizza CR, McMichael AJ, Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453, 1991
Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E, Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352:436, 1991
Reitz MM, Wilson C, Naugle C, Gallo RC, Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope. Cell 54:57, 1990
Robert-Guroff M, Brown M, Gallo RC, HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 316:72, 1985
Robert-Guroff M, Reitz MS, Robey WG, Gallo RC In vitro generation of a HTLV-III variant by neutralizing antibody. J Immunol 137:3306, 1990
Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimalia R, Langlois A, Gall R, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, Matthews TJ, Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope gp120. Proc Natl Acad Sci USA 85:3198, 1988
Stott EJ, Anti-cell antibody in macaques. Nature 353:393, 1991
Sutjipto S, Pedersen NC, Miller CJ, Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J Virol 64:2290, 1990
Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL Delisi C, Moss B, Germain RN, Berzofsky JA, An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85:3105, 1988
Tsubota H, Lord CI, Watkins DI, Morimoto C, Letvin NL, A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 169:1421, 1989
Walker BD, Flexner C, Birch-Limberger K, Fischer L, Paradis TJ, Aldoni A, Young R, Moss B, Schooley RT, Long-term culture and fine specificity of human T lymphocyte clones reactive with HIV-1. Proc Natl Acad Sci USA 86:9514, 1989
Walker CM, Moody DJ, Stites DP, Levy JA, CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ennen, J., Norley, S.G. & Kurth, R. AIDS vaccine: present problems and future perspectives. Int J Clin Lab Res 22, 206–210 (1992). https://doi.org/10.1007/BF02591425
Issue Date:
DOI: https://doi.org/10.1007/BF02591425